• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Carcinomas - Pipeline Review, H2 2012 Product Image

Carcinomas - Pipeline Review, H2 2012

  • Published: December 2012
  • 319 pages
  • Global Markets Direct

Carcinomas – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Carcinomas - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinomas. Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 11
List of Figures 15
Introduction 16
REPORT COVERAGE 16
Carcinomas Overview 17
Therapeutics Development 18
An Overview of Pipeline Products for Carcinomas 18
Carcinomas Therapeutics under Development by Companies 20
Carcinomas Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Carcinomas Therapeutics – Products under Development by Companies 43
Carcinomas Therapeutics – Products under Investigation by Universities/Institutes 51
Companies Involved in Carcinomas Therapeutics Development 77
Boehringer Ingelheim GmbH 77
F. Hoffmann-La Roche Ltd. 78
Abbott Laboratories 79
Sequella, Inc. 80
Shionogi & Co., Ltd. 81
Amgen Inc. 82
Sanofi-Aventis 83
AstraZeneca PLC 84
Eli Lilly and Company 85
GlaxoSmithKline plc 86
Genentech, Inc. 87
Gilead Sciences, Inc. 88
Merck & Co., Inc. 89
YM BioSciences Inc. 90
Delcath Systems, Inc. 91
Celltrion, Inc. 92
Millennium Pharmaceuticals, Inc. 93
Novartis AG 94
Astellas Pharma Inc. 95
Eisai Co., Ltd. 96
Pfizer Inc. 97
Taiho Pharmaceutical Co., Ltd. 98
Takara Holdings Inc. 99
Yakult Honsha Co., Ltd. 100
Aduro BioTech 101
CEL-SCI Corporation 102
Celgene Corporation 103
Merck KGaA 104
Alchemia Limited 105
Celldex Therapeutics, Inc. 106
Momenta Pharmaceuticals, Inc. 107
Idera Pharmaceuticals, Inc. 108
Lorus Therapeutics Inc 109
AVAX Technologies, Inc. 110
NexMed, Inc. 111
Clinuvel Pharmaceuticals Limited 112
Oncothyreon Inc 113
Peregrine Pharmaceuticals, Inc. 114
TopoTarget A/S 115
Eleison Pharmaceuticals, Inc. 139
Vakzine Projekt Management GmbH 140
Eurofarma 141
Laboratorio Elea S.A.C.I.F. and A 142
Biotech Pharmaceuticals Co., Ltd. 143
Carcinomas – Therapeutics Assessment 144
Assessment by Monotherapy Products 144
Assessment by Combination Products 145
Drug Profiles 146
glufosfamide - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
iniparib - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
Cetuximab + Gemcitabine Hydrochloride - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
Cisplatin + Navelbine - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Tegafur + Uracil + Leucovorin + Polysaccharide-K - Drug Profile 196
Product Description 196
Mechanism of Action 196
R&D Progress 196
Cisplatin + Fluorouracil - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
Cisplatin + Fluorouracil - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Cyclophosphamide + Cisplatin - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
Cetuximab + Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin - Drug Profile 203
Product Description 203
Mechanism of Action 203
R&D Progress 203
Tarceva + Cisplatin + Paclitaxel - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 205
Omegaven + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 221
Product Description 221
Mechanism of Action 221
R&D Progress 222
Tracitrans Plus + 5-Fluorouracil + Folinic acid + Oxaliplatin - Drug Profile 223
Product Description 223
Mechanism of Action 223
R&D Progress 223
Carboplatin + Radiation Therapy - Drug Profile 225
Product Description 225
Mechanism of Action 225
R&D Progress 225
Nedaplatin + Docetaxel - Drug Profile 226
Product Description 226
Mechanism of Action 226
R&D Progress 226
Cisplatin + Docetaxel - Drug Profile 227
Product Description 227
Mechanism of Action 227
R&D Progress 227
Nimotuzumab + Cisplatin + Radiotherapy - Drug Profile 228
Product Description 228
Mechanism of Action 228
R&D Progress 228
Mitomycin C + Epirubicin + Cisplatin + 5-Fluorouracil + Leucovorin - Drug Profile 230
Product Description 230
Mechanism of Action 230
R&D Progress 231
Panitumumab - Drug Profile 232
Product Description 232
Mechanism of Action 232
R&D Progress 232
cyclophosphamide - Drug Profile 233
Product Description 233
Mechanism of Action 233
R&D Progress 233
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan - Drug Profile 234
Product Description 234
Mechanism of Action 234
R&D Progress 235
Flutamide + Goserelin + Leuprolide - Drug Profile 236
Product Description 236
Mechanism of Action 236
R&D Progress 237
sorafenib tosylate - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 240
C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 243
cisplatin - Drug Profile 244
Product Description 244
Mechanism of Action 244
R&D Progress 244
IMC-1121B + FOLFIRI - Drug Profile 246
Product Description 246
Mechanism of Action 246
R&D Progress 246
Erbitux + Radiation Therapy - Drug Profile 248
Product Description 248
Mechanism of Action 248
R&D Progress 248
Paclitaxel + RAD001 - Drug Profile 249
Product Description 249
Mechanism of Action 249
R&D Progress 249
IMC-1121B + Paclitaxel - Drug Profile 250
Product Description 250
Mechanism of Action 250
R&D Progress 250
Trastuzumab + Carboplatin + Paclitaxel - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 252
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
Gemcitabine + Human Epidermal Growth Factor Receptor Type I - Drug Profile 255
Product Description 255
Mechanism of Action 255
R&D Progress 255
TPF Induction Chemotherapy + Radiotherapy - Drug Profile 256
Product Description 256
Mechanism of Action 256
R&D Progress 257
Cisplatin + 5-Fluorouracil + Leucovorin + Irinotecan + Docetaxel - Drug Profile 257
Product Description 257
Mechanism of Action 257
R&D Progress 258
Carcinomas Therapeutics – Drug Profile Updates 259
Carcinomas Therapeutics – Discontinued Products 267
Carcinomas Therapeutics - Dormant Products 274
Carcinomas – Product Development Milestones 310
Featured News & Press Releases 310
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 310
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 310
Jul 16, 2012: Peregrine Initiates Phase I Rectal Adenocarcinoma Investigator Sponsored Trial 311
Jul 06, 2012: Navidea To Present Data From Lymphoseek Program At Upcoming Upcoming Scientific Meetings In July 312
Jun 29, 2012: Topotarget Announces Top-Line Results From Phase II Trial Of Belinostat For Treatment Of Cancer 313
Jun 02, 2012: Oncothyreon Provides Update On PX-866 Phase II Program 313
Mar 15, 2012: Bio-Cancer Treatment International Obtains FDA Approval To Initiate Phase I Study Of Cancer Drug PEG-BCT-100 314
Dec 07, 2011: CEL- SCI Updates Phase III Clinical Activities For Multikine 315
Nov 13, 2011: Oncothyreon Presents Data From Phase I/II Trials Of PX-866 In Combination With Docetaxel At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 315
Nov 13, 2011: Oncothyreon Presents Data From Phase I/II Trials Of PX-866 In Combination With Cetuximab At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 316
Appendix 318
Methodology 318
Coverage 318
Secondary Research 318
Primary Research 318
Expert Panel Validation 318
Contact Us 319
Disclaimer 319

List of Tables
Number of Products Under Development for Carcinomas, H2 2012 18
Products under Development for Carcinomas – Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Development by Companies, H2 2012 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 38
Comparative Analysis by Late Stage Development, H2 2012 39
Comparative Analysis by Mid Clinical Stage Development, H2 2012 40
Comparative Analysis by Early Clinical Stage Development, H2 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 42
Products under Development by Companies, H2 2012 43
Products under Development by Companies, H2 2012 (Contd..1) 44
Products under Development by Companies, H2 2012 (Contd..2) 45
Products under Development by Companies, H2 2012 (Contd..3) 46
Products under Development by Companies, H2 2012 (Contd..4) 47
Products under Development by Companies, H2 2012 (Contd..5) 48
Products under Development by Companies, H2 2012 (Contd..6) 49
Products under Development by Companies, H2 2012 (Contd..7) 50
Products under Investigation by Universities/Institutes, H2 2012 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 76
Boehringer Ingelheim GmbH, H2 2012 77
F. Hoffmann-La Roche Ltd., H2 2012 78
Abbott Laboratories, H2 2012 79
Sequella, Inc., H2 2012 80
Shionogi & Co., Ltd., H2 2012 81
Amgen Inc., H2 2012 82
Sanofi-Aventis, H2 2012 83
AstraZeneca PLC, H2 2012 84
Eli Lilly and Company, H2 2012 85
GlaxoSmithKline plc, H2 2012 86
Genentech, Inc., H2 2012 87
Gilead Sciences, Inc., H2 2012 88
Merck & Co., Inc., H2 2012 89
YM BioSciences Inc., H2 2012 90
Delcath Systems, Inc., H2 2012 91
Celltrion, Inc., H2 2012 92
Millennium Pharmaceuticals, Inc., H2 2012 93
Novartis AG, H2 2012 94
Astellas Pharma Inc., H2 2012 95
Eisai Co., Ltd., H2 2012 96
Pfizer Inc., H2 2012 97
Taiho Pharmaceutical Co., Ltd., H2 2012 98
Takara Holdings Inc., H2 2012 99
Yakult Honsha Co., Ltd., H2 2012 100
Aduro BioTech, H2 2012 101
CEL-SCI Corporation, H2 2012 102
Celgene Corporation, H2 2012 103
Merck KGaA, H2 2012 104
Alchemia Limited, H2 2012 105
Celldex Therapeutics, Inc., H2 2012 106
Momenta Pharmaceuticals, Inc., H2 2012 107
Idera Pharmaceuticals, Inc., H2 2012 108
Lorus Therapeutics Inc, H2 2012 109
AVAX Technologies, Inc., H2 2012 110
NexMed, Inc., H2 2012 111
Clinuvel Pharmaceuticals Limited, H2 2012 112
Oncothyreon Inc, H2 2012 113
Peregrine Pharmaceuticals, Inc., H2 2012 114
TopoTarget A/S, H2 2012 115
Institute of Cancer Research, H2 2012 116
Threshold Pharmaceuticals, Inc., H2 2012 117
Provectus Pharmaceuticals, Inc., H2 2012 118
Proteo, Inc., H2 2012 119
Oryzon, H2 2012 120
PCI Biotech Holding ASA, H2 2012 121
Spectrum Pharmaceuticals, Inc., H2 2012 122
GANYMED Pharmaceuticals AG, H2 2012 123
Nerviano Medical Sciences S.r.l., H2 2012 124
Glycotope GmbH, H2 2012 125
immatics biotechnologies GmbH, H2 2012 126
Merrimack Pharmaceuticals, Inc., H2 2012 127
Jennerex Biotherapeutics, Inc., H2 2012 128
BioCancell Therapeutics, Inc., H2 2012 129
Omeros Corporation, H2 2012 130
Cellceutix Corporation, H2 2012 131
Kinex Pharmaceuticals, LLC, H2 2012 132
Cannabis Science, Inc., H2 2012 133
Genelux Corporation, H2 2012 134
Nereus Pharmaceuticals, Inc., H2 2012 135
Viventia Biotechnologies Inc., H2 2012 136
Lytix Biopharma AS, H2 2012 137
IRX Therapeutics, Inc., H2 2012 138
Eleison Pharmaceuticals, Inc., H2 2012 139
Vakzine Projekt Management GmbH, H2 2012 140
Eurofarma, H2 2012 141
Laboratorio Elea S.A.C.I.F. and A, H2 2012 142
Biotech Pharmaceuticals Co., Ltd., H2 2012 143
Assessment by Monotherapy Products, H2 2012 144
Assessment by Combination Products, H2 2012 145
Carcinomas Therapeutics – Drug Profile Updates 259
Carcinomas Therapeutics – Discontinued Products 267
Carcinomas Therapeutics – Discontinued Products (Contd..1) 268
Carcinomas Therapeutics – Discontinued Products (Contd..2) 269
Carcinomas Therapeutics – Discontinued Products (Contd..3) 270
Carcinomas Therapeutics – Discontinued Products (Contd..4) 271
Carcinomas Therapeutics – Discontinued Products (Contd..5) 272
Carcinomas Therapeutics – Discontinued Products (Contd..6) 273
Carcinomas Therapeutics – Dormant Products 274
Carcinomas Therapeutics – Dormant Products (Contd..1) 275
Carcinomas Therapeutics – Dormant Products (Contd..2) 276
Carcinomas Therapeutics – Dormant Products (Contd..3) 277
Carcinomas Therapeutics – Dormant Products (Contd..4) 278
Carcinomas Therapeutics – Dormant Products (Contd..5) 279
Carcinomas Therapeutics – Dormant Products (Contd..6) 280
Carcinomas Therapeutics – Dormant Products (Contd..7) 281
Carcinomas Therapeutics – Dormant Products (Contd..8) 282
Carcinomas Therapeutics – Dormant Products (Contd..9) 283
Carcinomas Therapeutics – Dormant Products (Contd..10) 284
Carcinomas Therapeutics – Dormant Products (Contd..11) 285
Carcinomas Therapeutics – Dormant Products (Contd..12) 286
Carcinomas Therapeutics – Dormant Products (Contd..13) 287
Carcinomas Therapeutics – Dormant Products (Contd..14) 288
Carcinomas Therapeutics – Dormant Products (Contd..15) 289
Carcinomas Therapeutics – Dormant Products (Contd..16) 290
Carcinomas Therapeutics – Dormant Products (Contd..17) 291
Carcinomas Therapeutics – Dormant Products (Contd..18) 292
Carcinomas Therapeutics – Dormant Products (Contd..19) 293
Carcinomas Therapeutics – Dormant Products (Contd..20) 294
Carcinomas Therapeutics – Dormant Products (Contd..21) 295
Carcinomas Therapeutics – Dormant Products (Contd..22) 296
Carcinomas Therapeutics – Dormant Products (Contd..23) 297
Carcinomas Therapeutics – Dormant Products (Contd..24) 298
Carcinomas Therapeutics – Dormant Products (Contd..25) 299
Carcinomas Therapeutics – Dormant Products (Contd..26) 300
Carcinomas Therapeutics – Dormant Products (Contd..27) 301
Carcinomas Therapeutics – Dormant Products (Contd..28) 302
Carcinomas Therapeutics – Dormant Products (Contd..29) 303
Carcinomas Therapeutics – Dormant Products (Contd..30) 304
Carcinomas Therapeutics – Dormant Products (Contd..31) 305
Carcinomas Therapeutics – Dormant Products (Contd..32) 306
Carcinomas Therapeutics – Dormant Products (Contd..33) 307
Carcinomas Therapeutics – Dormant Products (Contd..34) 308
Carcinomas Therapeutics – Dormant Products (Contd..35) 309

List of Figures
Number of Products under Development for Carcinomas, H2 2012 18
Products under Development for Carcinomas – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 144
Assessment by Combination Products, H2 2012 145

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos